Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer.

Cohen CW, Fontaine KR, Arend RC, Alvarez RD, Leath CA III, Huh WK, Bevis KS, Kim KH, Straughn JM Jr, Gower BA.

J Nutr. 2018 Aug 1;148(8):1253-1260. doi: 10.1093/jn/nxy119.

PMID:
30137481
2.

FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.

Kreitzburg KM, Fehling SC, Landen CN, Gamblin TL, Vance RB, Arend RC, Katre AA, Oliver PG, van Waardenburg RCAM, Alvarez RD, Yoon KJ.

Cancer Lett. 2018 Nov 1;436:75-86. doi: 10.1016/j.canlet.2018.08.015. Epub 2018 Aug 16.

PMID:
30120964
3.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. eCollection 2018 Apr 10.

4.

Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP).

Ko EM, Havrilesky LJ, Alvarez RD, Zivanovic O, Boyd LR, Jewell EL, Timmins PF 3rd, Gibb RS, Jhingran A, Cohn DE, Dowdy SC, Powell MA, Chalas E, Huang Y, Rathbun J, Wright JD.

Gynecol Oncol. 2018 May;149(2):232-240. doi: 10.1016/j.ygyno.2018.02.010. Epub 2018 Mar 13.

PMID:
29544708
5.

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Arend RC, Londoño AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM Jr, Estes JM, Novak L, Crossman DK, Cooper SJ, Landen CN, Leath CA 3rd.

Mol Cancer Res. 2018 May;16(5):813-824. doi: 10.1158/1541-7786.MCR-17-0594. Epub 2018 Mar 9.

PMID:
29523763
6.

Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model.

Wright JD, Havrilesky LJ, Cohn DE, Huang Y, Rathbun J, Rice LW, Brown CL, Alvarez RD, Ko EM.

Gynecol Oncol. 2018 May;149(2):241-247. doi: 10.1016/j.ygyno.2018.02.011. Epub 2018 Mar 1.

PMID:
29496293
7.

Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.

Barrington DA, Champion ML, Boitano TKL, Walters-Haygood CL, Farmer MB, Alvarez RD, Estes JM, Leath CA 3rd.

Gynecol Oncol. 2018 May;149(2):337-340. doi: 10.1016/j.ygyno.2018.02.014. Epub 2018 Mar 2.

PMID:
29486991
8.

Values and worries of ovarian cancer patients.

Pisu M, Kenzik KM, Rim SH, Funkhouser EM, Bevis KS, Alvarez RD, Cantuaria G, Rocconi RP, Martin MY.

Gynecol Oncol. 2017 Nov;147(2):433-438. doi: 10.1016/j.ygyno.2017.08.028. Epub 2017 Sep 7.

9.

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.

Herzog TJ, Ison G, Alvarez RD, Balasubramaniam S, Armstrong DK, Beaver JA, Ellis A, Tang S, Ford P, McKee A, Gershenson DM, Kim G, Monk BJ, Pazdur R, Coleman RL.

Gynecol Oncol. 2017 Oct;147(1):3-10. doi: 10.1016/j.ygyno.2017.08.012. Epub 2017 Aug 24. Review. No abstract available.

PMID:
28844539
10.
11.

The times they are a-changin' - Transformation of accreditation and certification in gynecologic oncology.

Alvarez RD, Fowler WC Jr.

Gynecol Oncol. 2017 May;145(2):221-223. doi: 10.1016/j.ygyno.2017.02.035. Epub 2017 Feb 28. No abstract available.

PMID:
28256320
12.

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.

Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, Straughn JM Jr, Dobelbower MC, Lowy AM.

Am J Clin Oncol. 2018 Jul;41(7):716-721. doi: 10.1097/COC.0000000000000353.

13.

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466. Erratum in: Oncotarget. 2018 Apr 10;9(27):19459.

14.

IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.

Thomas ED, Meza-Perez S, Bevis KS, Randall TD, Gillespie GY, Langford C, Alvarez RD.

J Ovarian Res. 2016 Oct 27;9(1):70.

15.

Evolving Paradigms in Research and Care in Ovarian Cancers.

Karlan BY, Alvarez RD, Strauss JF 3rd.

Obstet Gynecol. 2016 Oct;128(4):771-4. doi: 10.1097/AOG.0000000000001623.

PMID:
27607869
16.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M.

J Natl Compr Canc Netw. 2016 Sep;14(9):1134-63.

PMID:
27587625
17.

Crosstalk between the mitochondrial fission protein, Drp1, and the cell cycle is identified across various cancer types and can impact survival of epithelial ovarian cancer patients.

Tanwar DK, Parker DJ, Gupta P, Spurlock B, Alvarez RD, Basu MK, Mitra K.

Oncotarget. 2016 Sep 13;7(37):60021-60037. doi: 10.18632/oncotarget.11047.

18.

Drawing the Line in Risk-Reducing Gynecologic Surgery in Women With a BRCA Mutation.

Leath CA, Huh WK, Alvarez RD.

JAMA Oncol. 2016 Nov 1;2(11):1409-1411. doi: 10.1001/jamaoncol.2016.1773. No abstract available.

PMID:
27367041
19.

Surveying the Landscape of Ovarian Cancer Research and Care.

Alvarez RD, Strauss JF 3rd.

Ann Intern Med. 2016 Sep 20;165(6):439-40. doi: 10.7326/M16-0604. Epub 2016 May 17. No abstract available.

PMID:
27183518
20.

"Ovarian cancers: Evolving paradigms in research and care": Report from the Institute of Medicine.

Alvarez RD, Karlan BY, Strauss JF.

Gynecol Oncol. 2016 Jun;141(3):413-415. doi: 10.1016/j.ygyno.2016.04.541. No abstract available.

PMID:
27138456
21.

Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.

Becker DA, Thomas ED, Gilbert AL, Boone JD, Straughn JM Jr, Huh WK, Bevis KS, Leath CA 3rd, Alvarez RD.

Gynecol Oncol. 2016 Jul;142(1):25-29. doi: 10.1016/j.ygyno.2016.04.539. Epub 2016 May 10.

PMID:
27130405
22.

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.

Alvarez RD, Matulonis UA, Herzog TJ, Coleman RL, Monk BJ, Markman M.

Gynecol Oncol. 2016 Jun;141(3):405-409. doi: 10.1016/j.ygyno.2016.03.005. Epub 2016 Apr 8. No abstract available.

PMID:
27049967
23.

Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses.

Piyathilake CJ, Ollberding NJ, Kumar R, Macaluso M, Alvarez RD, Morrow CD.

Cancer Prev Res (Phila). 2016 May;9(5):357-66. doi: 10.1158/1940-6207.CAPR-15-0350. Epub 2016 Mar 2.

24.

Report on NRG Oncology and the GOG Foundation.

Alvarez RD.

Gynecol Oncol. 2016 Mar;140(3):381-2. doi: 10.1016/j.ygyno.2016.02.010. No abstract available.

PMID:
26905435
25.

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.

Kim KH, Jelovac D, Armstrong DK, Schwartz B, Weil SC, Schweizer C, Alvarez RD.

Gynecol Oncol. 2016 Feb;140(2):210-4. doi: 10.1016/j.ygyno.2015.11.031. Epub 2015 Nov 28.

26.

Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance.

Minion LE, Coleman RL, Alvarez RD, Herzog TJ.

Gynecol Oncol. 2016 Feb;140(2):193-8. doi: 10.1016/j.ygyno.2015.11.030. Epub 2015 Nov 26.

PMID:
26631607
27.

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).

Alvarez RD, Huh WK, Bae S, Lamb LS Jr, Conner MG, Boyer J, Wang C, Hung CF, Sauter E, Paradis M, Adams EA, Hester S, Jackson BE, Wu TC, Trimble CL.

Gynecol Oncol. 2016 Feb;140(2):245-52. doi: 10.1016/j.ygyno.2015.11.026. Epub 2015 Nov 23.

28.

The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study.

Rocconi RP, Lankes HA, Brady WE, Goodfellow PJ, Ramirez NC, Alvarez RD, Creasman W, Fernández JR.

Gynecol Oncol. 2016 Feb;140(2):264-9. doi: 10.1016/j.ygyno.2015.11.018. Epub 2015 Nov 18.

29.

Report on NRG Oncology and the GOG Foundation.

Alvarez RD.

Gynecol Oncol. 2015 Oct;139(1):3-4. doi: 10.1016/j.ygyno.2015.08.021. Epub 2015 Aug 31. No abstract available.

PMID:
26325528
30.

Consensus in controversy: The modified Delphi method applied to Gynecologic Oncology practice.

Cohn DE, Havrilesky LJ, Osann K, Lipscomb J, Hsieh S, Walker JL, Wright AA, Alvarez RD, Karlan BY, Bristow RE, DiSilvestro PA, Wakabayashi MT, Morgan R, Mukamel DB, Wenzel L.

Gynecol Oncol. 2015 Sep;138(3):712-6. doi: 10.1016/j.ygyno.2015.07.014. Epub 2015 Jul 12.

31.

Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project.

Shah MM, Leath CA 3rd, Daily LR, McGwin G Jr, Estes JM, Alvarez RD, Straughn JM Jr.

Int J Gynecol Cancer. 2015 Jun;25(5):798-801. doi: 10.1097/IGC.0000000000000433.

32.

In assessing surrogate clinical trial end points: drug safety is a requisite.

Herzog TJ, Coleman RL, Monk BJ, Armstrong DK, Alvarez RD.

J Clin Oncol. 2015 May 1;33(13):1511-2. doi: 10.1200/JCO.2014.59.8169. Epub 2015 Mar 2. No abstract available.

PMID:
25732164
33.

Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.

Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB.

PLoS One. 2015 Jan 5;10(1):e116389. doi: 10.1371/journal.pone.0116389. eCollection 2015.

34.

Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.

Erickson BK, Kinde I, Dobbin ZC, Wang Y, Martin JY, Alvarez RD, Conner MG, Huh WK, Roden RB, Kinzler KW, Papadopoulos N, Vogelstein B, Diaz LA Jr, Landen CN Jr.

Obstet Gynecol. 2014 Nov;124(5):881-5. doi: 10.1097/AOG.0000000000000484.

35.

Monitoring of biodistribution and persistence of conditionally replicative adenovirus in a murine model of ovarian cancer using capsid-incorporated mCherry and expression of human somatostatin receptor subtype 2 gene.

Dmitriev IP, Kashentseva EA, Kim KH, Matthews QL, Krieger SS, Parry JJ, Nguyen KN, Akers WJ, Achilefu S, Rogers BE, Alvarez RD, Curiel DT.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00024.

PMID:
25249483
36.

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.

Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, Conner MG, Schneider D, Chen D, Landen CN.

Oncotarget. 2014 Sep 30;5(18):8750-64.

37.

Report on NRG Oncology and the GOG Partners Program.

Alvarez RD.

Gynecol Oncol. 2014 Sep;134(3):445-6. doi: 10.1016/j.ygyno.2014.08.002. No abstract available.

PMID:
25199579
38.

Folate and vitamin B12 may play a critical role in lowering the HPV 16 methylation-associated risk of developing higher grades of CIN.

Piyathilake CJ, Macaluso M, Chambers MM, Badiga S, Siddiqui NR, Bell WC, Edberg JC, Partridge EE, Alvarez RD, Johanning GL.

Cancer Prev Res (Phila). 2014 Nov;7(11):1128-37. doi: 10.1158/1940-6207.CAPR-14-0143. Epub 2014 Aug 21.

39.

SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.

Herzog TJ, Alvarez RD, Secord A, Goff BA, Mannel RS, Monk BJ, Coleman RL.

Gynecol Oncol. 2014 Oct;135(1):3-7. doi: 10.1016/j.ygyno.2014.08.004. Epub 2014 Aug 12.

40.

An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.

Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN.

Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15.

41.

Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.

Arend RC, Londoño-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM, Buchsbaum DJ.

Gynecol Oncol. 2014 Jul;134(1):112-20. doi: 10.1016/j.ygyno.2014.04.005. Epub 2014 Apr 13.

PMID:
24736023
42.
43.

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.

Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK.

Gynecol Oncol. 2014 Jun;133(3):433-8. doi: 10.1016/j.ygyno.2014.03.571. Epub 2014 Apr 4.

44.

Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells.

Peng S, Song L, Knoff J, Wang JW, Chang YN, Hannaman D, Wu TC, Alvarez RD, Roden RB, Hung CF.

Cell Biosci. 2014 Mar 4;4(1):11. doi: 10.1186/2045-3701-4-11.

45.

Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors.

Wu CY, Yang LH, Yang HY, Knoff J, Peng S, Lin YH, Wang C, Alvarez RD, Pai SI, Roden RB, Hung CF, Wu TC.

Clin Cancer Res. 2014 Feb 1;20(3):644-57. doi: 10.1158/1078-0432.CCR-13-1334. Epub 2013 Dec 3.

46.

Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD.

Gynecol Oncol. 2014 Jan;132(1):8-17. doi: 10.1016/j.ygyno.2013.11.008. Epub 2013 Nov 15.

47.

Ovarian cancer, version 2.2013.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M; National comprehensive cancer networks.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209.

PMID:
24142821
48.

Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.

Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD.

Gynecol Oncol. 2013 Nov;131(2):493-8. doi: 10.1016/j.ygyno.2013.07.080. Epub 2013 Jul 14. Review.

PMID:
23863359
49.

Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.

Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D, Alvarez RD.

Gynecol Oncol. 2013 Oct;131(1):169-73. doi: 10.1016/j.ygyno.2013.07.081. Epub 2013 Jul 14. Erratum in: Gynecol Oncol. 2014 Jul;134(1):216.

PMID:
23863356
50.

A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, Bae S, Singh KP, Siegal GP, Curiel DT, Alvarez RD.

Gynecol Oncol. 2013 Sep;130(3):518-24. doi: 10.1016/j.ygyno.2013.06.003. Epub 2013 Jun 10.

Supplemental Content

Loading ...
Support Center